Bypassing NK cell limitations in the tumor microenvironment through novel Poly-Antigen Cytokine Complexes 2287
Martin Felices(University of Minnesota), Jeffrey S. Miller(Science Museum of Minnesota), Pippa Kennedy(University of Minnesota), Bruce Walcheck(University of Veterinary Science), Melissa A. Geller(University of Minnesota), Yvette Soignier(University of Minnesota System), Mihir Shetty(University of Minnesota), Zhenya Ni(University of Minnesota), Melissa Khaw(University of Minnesota), Laura E. Bendzick(University of Minnesota), Anna Weis(University of Minnesota), Marieke van Breukelen(University of Minnesota), Anders W. Matson(University of Minnesota), Emma M Eungard(University of Minnesota), Joshua T. Walker(University of Minnesota System)
Cited by 0
Related Papers
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
|Blood|2013|537
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2019|533
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
|Blood|2018|406
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
|Clinical Cancer Research|2018|195